BioSpace News Archive

Zimmer Biomet Holdings, Inc., a global medical technology leader, announced one-year data from a multicenter, prospective, randomized controlled trial to evaluate the impact of mymobility® with Apple Watch, a first-of-its-kind remote care management platform.

Vera Therapeutics, Inc., a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, announced new clinical data presented on the Company’s two product candidates, atacicept in immunoglobulin A nephropathy and MAU868 in kidney transplant.

Silence Therapeutics plc, presented data from an analysis of its APOLLO phase 1 single dose study of SLN360, an investigational short interfering ribonucleic acid, in healthy adults with high lipoprotein, a key genetic risk factor for heart disease, at the American Heart Association 2022 Annual Meeting.

89bio, Inc. announced the presentation of post-hoc exploratory analyses of additional data from the paired-biopsy, open-label expansion cohort in the Phase 1b/2a proof-of-concept study evaluating pegozafermin in patients with nonalcoholic steatohepatitis.

Horizon Therapeutics plc announced new data that indicate KRYSTEXXA injection with weekly oral methotrexate effectively treats uncontrolled gout without compromising kidney function.

Intellia Therapeutics, Inc. presented additional interim results from an ongoing Phase 1 clinical trial of NTLA-2001, an investigational, in vivo CRISPR/Cas9 genome editing therapy in development as a single-dose treatment for transthyretin amyloidosis in collaboration with Regeneron Pharmaceuticals.

Lexicon Pharmaceuticals, Inc. announced that a new post hoc analysis of results from the SCORED Phase 3 outcomes trial of sotagliflozin, an investigational dual SGLT1 and SGLT2 inhibitor, was presented at the American Society of Nephrology Kidney Week 2022 annual scientific meeting in Orlando, Florida.